Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 15/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13990698 | 0.83 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL28478563 | 0.83 | MAOA (0.50) | KDM4EALDH1A1SMN1; SMN2MCL1CYP3A4 | |
| SCHEMBL18184325 | 0.83 | TEAD4 (0.50) | KDM4EALDH1A1SMN1; SMN2MCL1CYP3A4 | |
| SCHEMBL21548254 | 0.80 | ALDH1A1 (0.64) | KDM4EALDH1A1SMN1; SMN2CYP3A4MAOA | |
| SCHEMBL6790339 | 0.79 | KMT2A (0.51) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL20415866 | 0.79 | LTA4H (0.52) | KDM4ESMN1; SMN2MCL1MAOABCL2L1 | |
| SCHEMBL20412261 | 0.78 | KDM4E (0.42) | KDM4EALDH1A1SMN1; SMN2MCL1BCL2L1 | |
| SCHEMBL24283599 | 0.77 | SLC6A4 (0.44) | KDM4EALDH1A1SMN1; SMN2MCL1CYP3A4 | |
| SCHEMBL17149393 | 0.77 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2MCL1BCL2L1 | |
| SCHEMBL18161361 | 0.77 | ALDH1A1 (0.53) | KDM4EALDH1A1SMN1; SMN2MCL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2020-12-08 | — | — | US | disclosed |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858316-B2 | Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof | MCL1, BCL3, BCL9 | KDM4E 2727/4885ALDH1A1 2863/4885SMN1; SMN2 3339/4885 |
| US-20180208554-A1 | Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof | MCL1, BCL3, BCL9 | KDM4E 2727/4885ALDH1A1 2863/4885SMN1; SMN2 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.